Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Clinical trial NCT03672539 · COMPLETED

Trial details

NCT number: NCT03672539
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia High Risk Myelodysplastic Syndrome Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2018-11-07
Primary completion: 2026-07-17
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.